Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 2021-12-01
MSI/dMMR tumors in perioperative setting Ended

2024-518127-30-00 MSI/dMMR tumors or EBV+ gastric cancer 2021-11-26
Efficacy and Safety of Afimetoran Compared with Placebo in Participants with Active Systemic Lupus Erythematosus Ended

2023-504320-25-00 Active Systemic Lupus Erythematosus 2021-11-25
Study of Nivolumab and Ipilimumab plus chemotherapy as a treatment for patients with stage IV lung cancer with brain metastases. Ended

2024-513866-20-00 Non-small cell lung cancer with brain metastasis 2021-11-18
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended

2024-513936-80-00 elderly patients (> 70 years) with CLL or SLL 2021-11-12
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended

2024-517965-18-00 Advanced NSCLC with common EGFR-Mutation 2021-11-11
An extension study for patients with PROS or Proteus Syndrome currently treated with miransertib Ended

2022-500689-87-00 PIK3CA-related overgrowth spectrum (PROS) and Proteus S 2021-11-05
Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma Ended

2023-507381-13-00 Relapsed/Refractory Peripheral T-Cell Lymphoma 2021-11-03
Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle… Ended

2023-509380-24-00 Metastatic upper gastrointestinal cancer, cancer of eso 2021-11-01
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Ended

2024-513605-31-00 Myelofibrosis 2021-10-21
Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with n… Ended

2024-515581-13-00 Isatuximab in combination with Lenalidomide-Dexamethaso 2021-10-20
Adjuvant therapy in stage IV colorectal cancer patients NED Ended

2024-518217-26-00 Stage IV colorectal cancer patients with no evidence of 2021-10-20
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended

2023-503441-55-00 Relapsed/Refractory Multiple Myeloma 2021-10-14
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia Ended

2022-502047-35-00 Yellow fever 2021-10-07
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended

2024-514122-23-00 Marginal Zone Lymphomas refractory to or in first or gr 2021-10-07
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Malignant Solid Tumors - Non Small Cell Lung Cancer 2021-09-22
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and therapeutic evaluation of symptomatic multiple mye… Ended

2024-516752-18-00 Multiple myeloma 2021-09-21
The ExPlas Study Ended

2024-518668-11-01 Early symptomatic phase Alzheimer's disease 2021-09-17
A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended

2024-513397-21-00 Relapsed Multiple Myeloma 2021-09-16
A study investigating what potential benefits adding AZD2811 might have to the current standard of care maintenance therapy of durvalumab in… Ended

2024-511887-10-00 First-line patients with extensive disease small-cell l 2021-09-14
A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM… Ended

2024-516986-35-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 2021-09-06
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Persistent or Recurrent Rare Epithelial Ovarian Tumors 2021-08-30
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended

2023-503905-12-00 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duc 2021-08-20
A Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With MM Who Are Refractory to at Least One PI, One IMiD and One Ant… Ended

2023-504479-25-00 Multiple myeloma 2021-08-20